REMDESIVIR - the only drug allowed during Covid19 had a 53% kill rate in EBOLA cases

The X post by Valerie Anne Smith discusses the controversial use of remdesivir during the COVID-19 pandemic, highlighting its initial rejection for Ebola trials due to a 53% mortality rate, yet its subsequent approval and widespread use in COVID-19 treatment despite known risks to kidney and liver function. This raises questions about the decision-making process and the influence of financial incentives, as hospitals were reportedly bribed with bonuses to administer the drug.
The post cites David Martin, an intellectual property analyst, who claims that remdesivir was deemed too unethical for African clinical trials but was pushed by figures like Anthony Fauci and Deborah Birx, despite the World Health Organization's eventual recommendation against its use. This discrepancy underscores a potential conflict of interest where financial gain may have overridden patient safety concerns.
Scientific evidence from peer-reviewed sources, such as the American Journal of Health-System Pharmacy, indicates that remdesivir was the costliest drug for hospitals in 2021 and 2022, despite a significant drop in expenditures, suggesting its extensive use. However, studies and reports, including those from the New Yorker, have criticized its efficacy and safety, pointing to alternative treatments like hydroxychloroquine and ivermectin, which were controversially dismissed despite some evidence of efficacy.
https://x.com/ValerieAnne1970/status/1925426521222590825